Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51


Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition.

Habets RA, de Bock CE, Serneels L, Lodewijckx I, Verbeke D, Nittner D, Narlawar R, Demeyer S, Dooley J, Liston A, Taghon T, Cools J, de Strooper B.

Sci Transl Med. 2019 May 29;11(494). pii: eaau6246. doi: 10.1126/scitranslmed.aau6246.


FAT1 cadherin controls neuritogenesis during NTera2 cell differentiation.

Ahmed AF, de Bock CE, Sontag E, Hondermarck H, Lincz LF, Thorne RF.

Biochem Biophys Res Commun. 2019 Jun 30;514(3):625-631. doi: 10.1016/j.bbrc.2019.04.197. Epub 2019 May 7.


T-cell acute lymphoblastic leukemias express a unique truncated FAT1 isoform that cooperates with NOTCH1 in leukemia development.

de Bock CE, Down M, Baidya K, Sweron B, Boyd AW, Fiers M, Burns GF, Molloy TJ, Lock RB, Soulier J, Taghon T, Van Vlierberghe P, Cools J, Holst J, Thorne RF.

Haematologica. 2019 May;104(5):e204-e207. doi: 10.3324/haematol.2018.198424. Epub 2018 Dec 4. No abstract available.


JAK3 mutations and HOXA9 expression are important cooperating events in T-cell acute lymphoblastic leukemia.

de Bock CE, Cools J.

Mol Cell Oncol. 2018 Apr 4;5(3):e1458014. doi: 10.1080/23723556.2018.1458014. eCollection 2018.


Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.

Degryse S, de Bock CE, Demeyer S, Govaerts I, Bornschein S, Verbeke D, Jacobs K, Binos S, Skerrett-Byrne DA, Murray HC, Verrills NM, Van Vlierberghe P, Cools J, Dun MD.

Leukemia. 2018 Dec;32(12):2731. doi: 10.1038/s41375-018-0241-7.


The CCR4-NOT complex is a tumor suppressor in Drosophila melanogaster eye cancer models.

Vicente C, Stirparo R, Demeyer S, de Bock CE, Gielen O, Atkins M, Yan J, Halder G, Hassan BA, Cools J.

J Hematol Oncol. 2018 Aug 25;11(1):108. doi: 10.1186/s13045-018-0650-0.


Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia.

Vanden Bempt M, Demeyer S, Broux M, De Bie J, Bornschein S, Mentens N, Vandepoel R, Geerdens E, Radaelli E, Bornhauser BC, Kulozik AE, Meijerink JP, Bourquin JP, de Bock CE, Cools J.

Cancer Cell. 2018 Aug 13;34(2):271-285.e7. doi: 10.1016/j.ccell.2018.07.007.


Malt1 self-cleavage is critical for regulatory T cell homeostasis and anti-tumor immunity in mice.

Baens M, Stirparo R, Lampi Y, Verbeke D, Vandepoel R, Cools J, Marynen P, de Bock CE, Bornschein S.

Eur J Immunol. 2018 Oct;48(10):1728-1738. doi: 10.1002/eji.201847597. Epub 2018 Aug 7.


A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing.

Verboom K, Van Loocke W, Volders PJ, Decaesteker B, Cobos FA, Bornschein S, de Bock CE, Atak ZK, Clappier E, Aerts S, Cools J, Soulier J, Taghon T, Van Vlierberghe P, Vandesompele J, Speleman F, Durinck K.

Haematologica. 2018 Dec;103(12):e585-e589. doi: 10.3324/haematol.2018.190587. Epub 2018 Jun 28. No abstract available.


HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.

de Bock CE, Demeyer S, Degryse S, Verbeke D, Sweron B, Gielen O, Vandepoel R, Vicente C, Vanden Bempt M, Dagklis A, Geerdens E, Bornschein S, Gijsbers R, Soulier J, Meijerink JP, Heinäniemi M, Teppo S, Bouvy-Liivrand M, Lohi O, Radaelli E, Cools J.

Cancer Discov. 2018 May;8(5):616-631. doi: 10.1158/2159-8290.CD-17-0583. Epub 2018 Mar 1.


Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.

Degryse S, Bornschein S, de Bock CE, Leroy E, Vanden Bempt M, Demeyer S, Jacobs K, Geerdens E, Gielen O, Soulier J, Harrison CJ, Constantinescu SN, Cools J.

Blood. 2018 Jan 25;131(4):421-425. doi: 10.1182/blood-2017-07-797597. Epub 2017 Nov 29.


miR-139-5p Modulates Radiotherapy Resistance in Breast Cancer by Repressing Multiple Gene Networks of DNA Repair and ROS Defense.

Pajic M, Froio D, Daly S, Doculara L, Millar E, Graham PH, Drury A, Steinmann A, de Bock CE, Boulghourjian A, Zaratzian A, Carroll S, Toohey J, O'Toole SA, Harris AL, Buffa FM, Gee HE, Hollway GE, Molloy TJ.

Cancer Res. 2018 Jan 15;78(2):501-515. doi: 10.1158/0008-5472.CAN-16-3105. Epub 2017 Nov 27.


Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system.

Bornschein S, Demeyer S, Stirparo R, Gielen O, Vicente C, Geerdens E, Ghesquière B, Aerts S, Cools J, de Bock CE.

Leukemia. 2018 Apr;32(4):941-951. doi: 10.1038/leu.2017.328. Epub 2017 Nov 20.


Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.

Degryse S, de Bock CE, Demeyer S, Govaerts I, Bornschein S, Verbeke D, Jacobs K, Binos S, Skerrett-Byrne DA, Murray HC, Verrills NM, Van Vlierberghe P, Cools J, Dun MD.

Leukemia. 2018 Mar;32(3):788-800. doi: 10.1038/leu.2017.276. Epub 2017 Aug 30. Erratum in: Leukemia. 2018 Dec;32(12):2731.


Protein interaction screening identifies SH3RF1 as a new regulator of FAT1 protein levels.

de Bock CE, Hughes MR, Snyder K, Alley S, Sadeqzadeh E, Dun MD, McNagny KM, Molloy TJ, Hondermarck H, Thorne RF.

FEBS Lett. 2017 Feb;591(4):667-678. doi: 10.1002/1873-3468.12569. Epub 2017 Feb 16.


Cell biology: A mitochondrial brake on vascular repair.

de Bock CE, Thorne RF.

Nature. 2016 Nov 24;539(7630):503-505. doi: 10.1038/nature20476. Epub 2016 Nov 9. No abstract available.


Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors.

Dagklis A, Demeyer S, De Bie J, Radaelli E, Pauwels D, Degryse S, Gielen O, Vicente C, Vandepoel R, Geerdens E, Uyttebroeck A, Boeckx N, de Bock CE, Cools J.

Blood. 2016 Dec 8;128(23):2642-2654. Epub 2016 Sep 30.


Generation of the Fip1l1-Pdgfra fusion gene using CRISPR/Cas genome editing.

Vanden Bempt M, Demeyer S, Mentens N, Geerdens E, De Bock CE, Wlodarska I, Cools J.

Leukemia. 2016 Sep;30(9):1913-6. doi: 10.1038/leu.2016.62. Epub 2016 Mar 8. No abstract available.


Characterization of the genome-wide TLX1 binding profile in T-cell acute lymphoblastic leukemia.

Durinck K, Van Loocke W, Van der Meulen J, Van de Walle I, Ongenaert M, Rondou P, Wallaert A, de Bock CE, Van Roy N, Poppe B, Cools J, Soulier J, Taghon T, Speleman F, Van Vlierberghe P.

Leukemia. 2015 Dec;29(12):2317-27. doi: 10.1038/leu.2015.162. Epub 2015 Jun 25.


FAT1 cadherin acts upstream of Hippo signalling through TAZ to regulate neuronal differentiation.

Ahmed AF, de Bock CE, Lincz LF, Pundavela J, Zouikr I, Sontag E, Hondermarck H, Thorne RF.

Cell Mol Life Sci. 2015 Dec;72(23):4653-69. doi: 10.1007/s00018-015-1955-6. Epub 2015 Jun 24.


T-ALL: Home Is where the CXCL12 Is.

de Bock CE, Cools J.

Cancer Cell. 2015 Jun 8;27(6):745-6. doi: 10.1016/j.ccell.2015.05.011.


ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.

Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, Degryse S, Canté-Barrett K, Briot D, Clappier E, Lammens T, De Moerloose B, Benoit Y, Poppe B, Meijerink JP, Cools J, Soulier J, Rabbitts TH, Taghon T, Speleman F, Van Vlierberghe P.

Blood. 2014 Dec 11;124(25):3738-47. doi: 10.1182/blood-2014-05-574566. Epub 2014 Oct 9.


JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.

Degryse S, de Bock CE, Cox L, Demeyer S, Gielen O, Mentens N, Jacobs K, Geerdens E, Gianfelici V, Hulselmans G, Fiers M, Aerts S, Meijerink JP, Tousseyn T, Cools J.

Blood. 2014 Nov 13;124(20):3092-100. doi: 10.1182/blood-2014-04-566687. Epub 2014 Sep 5.


Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma.

Oliveira CS, de Bock CE, Molloy TJ, Sadeqzadeh E, Geng XY, Hersey P, Zhang XD, Thorne RF.

BMC Cancer. 2014 Aug 29;14:630. doi: 10.1186/1471-2407-14-630.


FAT1 cadherin is multiply phosphorylated on its ectodomain but phosphorylation is not catalysed by the four-jointed homologue.

Sadeqzadeh E, de Bock CE, O'Donnell MR, Timofeeva A, Burns GF, Thorne RF.

FEBS Lett. 2014 Sep 17;588(18):3511-7. doi: 10.1016/j.febslet.2014.08.014. Epub 2014 Aug 19.


A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain shedding.

Wojtalewicz N, Sadeqzadeh E, Weiß JV, Tehrani MM, Klein-Scory S, Hahn S, Schmiegel W, Warnken U, Schnölzer M, de Bock CE, Thorne RF, Schwarte-Waldhoff I.

PLoS One. 2014 Mar 13;9(3):e90461. doi: 10.1371/journal.pone.0090461. eCollection 2014.


Furin processing dictates ectodomain shedding of human FAT1 cadherin.

Sadeqzadeh E, de Bock CE, Wojtalewicz N, Holt JE, Smith ND, Dun MD, Schwarte-Waldhoff I, Thorne RF.

Exp Cell Res. 2014 Apr 15;323(1):41-55. doi: 10.1016/j.yexcr.2014.02.012. Epub 2014 Feb 18.


Sleeping giants: emerging roles for the fat cadherins in health and disease.

Sadeqzadeh E, de Bock CE, Thorne RF.

Med Res Rev. 2014 Jan;34(1):190-221. doi: 10.1002/med.21286. Epub 2013 May 29. Review.


PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma.

Ye Y, Jin L, Wilmott JS, Hu WL, Yosufi B, Thorne RF, Liu T, Rizos H, Yan XG, Dong L, Tay KH, Tseng HY, Guo ST, de Bock CE, Jiang CC, Wang CY, Wu M, Zhang LJ, Hersey P, Scolyer RA, Zhang XD.

Nat Commun. 2013;4:1508. doi: 10.1038/ncomms2489.


Fat1 cadherin provides a novel minimal residual disease marker in acute lymphoblastic leukemia.

Ardjmand A, de Bock CE, Shahrokhi S, Lincz LF, Boyd AW, Burns GF, Thorne RF.

Hematology. 2013 Nov;18(6):315-22. doi: 10.1179/1607845413Y.0000000080. Epub 2013 Feb 20.


The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia.

de Bock CE, Ardjmand A, Molloy TJ, Bone SM, Johnstone D, Campbell DM, Shipman KL, Yeadon TM, Holst J, Spanevello MD, Nelmes G, Catchpoole DR, Lincz LF, Boyd AW, Burns GF, Thorne RF.

Leukemia. 2012 May;26(5):918-26. doi: 10.1038/leu.2011.319. Epub 2011 Nov 25.


Dual processing of FAT1 cadherin protein by human melanoma cells generates distinct protein products.

Sadeqzadeh E, de Bock CE, Zhang XD, Shipman KL, Scott NM, Song C, Yeadon T, Oliveira CS, Jin B, Hersey P, Boyd AW, Burns GF, Thorne RF.

J Biol Chem. 2011 Aug 12;286(32):28181-91. doi: 10.1074/jbc.M111.234419. Epub 2011 Jun 16.


Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress.

Dong L, Jiang CC, Thorne RF, Croft A, Yang F, Liu H, de Bock CE, Hersey P, Zhang XD.

Oncogene. 2011 Aug 25;30(34):3716-26. doi: 10.1038/onc.2011.87. Epub 2011 Mar 21.


Novel protein interactors of urokinase-type plasminogen activator receptor.

Mekkawy AH, De Bock CE, Lin Z, Morris DL, Wang Y, Pourgholami MH.

Biochem Biophys Res Commun. 2010 Sep 3;399(4):738-43. doi: 10.1016/j.bbrc.2010.08.010. Epub 2010 Aug 7.


Palmitoylation of CD36/FAT regulates the rate of its post-transcriptional processing in the endoplasmic reticulum.

Thorne RF, Ralston KJ, de Bock CE, Mhaidat NM, Zhang XD, Boyd AW, Burns GF.

Biochim Biophys Acta. 2010 Nov;1803(11):1298-307. doi: 10.1016/j.bbamcr.2010.07.002. Epub 2010 Jul 13.


Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo.

de Bock CE, Garg MB, Scott N, Sakoff JA, Scorgie FE, Ackland SP, Lincz LF.

Pharmacogenomics J. 2011 Aug;11(4):307-14. doi: 10.1038/tpj.2010.43. Epub 2010 Jun 8.


Interaction between urokinase receptor and heat shock protein MRJ enhances cell adhesion.

De Bock CE, Lin Z, Mekkawy AH, Byrne JA, Wang Y.

Int J Oncol. 2010 May;36(5):1155-63.


The oasis effect: response of birds to exurban development in a southwestern savanna.

Bock CE, Jones ZF, Bock JH.

Ecol Appl. 2008 Jul;18(5):1093-106.


Mutations in GDF6 are associated with vertebral segmentation defects in Klippel-Feil syndrome.

Tassabehji M, Fang ZM, Hilton EN, McGaughran J, Zhao Z, de Bock CE, Howard E, Malass M, Donnai D, Diwan A, Manson FD, Murrell D, Clarke RA.

Hum Mutat. 2008 Aug;29(8):1017-27. doi: 10.1002/humu.20741.


Melanoma cell sensitivity to Docetaxel-induced apoptosis is determined by class III beta-tubulin levels.

Mhaidat NM, Thorne RF, de Bock CE, Zhang XD, Hersey P.

FEBS Lett. 2008 Jan 23;582(2):267-72. Epub 2007 Dec 18.


Relationships between species richness, evenness, and abundance in a southwestern savanna.

Bock CE, Jones ZF, Bock JH.

Ecology. 2007 May;88(5):1322-7.


Pleistocene rewilding: an optimistic agenda for twenty-first century conservation.

Josh Donlan C, Berger J, Bock CE, Bock JH, Burney DA, Estes JA, Foreman D, Martin PS, Roemer GW, Smith FA, Soulé ME, Greene HW.

Am Nat. 2006 Nov;168(5):660-81. Epub 2006 Sep 25.


Rodent communities in an exurbanizing southwestern landscape (U.S.A.).

Bock CE, Jones ZE, Bock JH.

Conserv Biol. 2006 Aug;20(4):1242-50.


Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells.

de Bock CE, Lin Z, Itoh T, Morris D, Murrell G, Wang Y.

FEBS J. 2005 Jul;272(14):3572-82.


Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer.

de Bock CE, Wang Y.

Med Res Rev. 2004 Jan;24(1):13-39. Review.


Spatial variation in diurnal surface temperatures and the distribution and abundance of an alpine grasshopper.

Coxwell CC, Bock CE.

Oecologia. 1995 Dec;104(4):433-439. doi: 10.1007/BF00341340.


Reptilian and avian ovarian cycles and the evolutionary origin of volant birds.

Jones RE, Smith HM, Bock CE.

J Theor Biol. 1993 Apr 21;161(4):527-36. Erratum in: J Theor Biol 1993 Dec 21;165(4):673.


Field experimental evidence for diffuse competition among Southwestern riparian birds.

Bock CE, Cruz A Jr, Grant MC, Aid CS, Strong TR.

Am Nat. 1992 Nov;140(5):815-28. doi: 10.1086/285442.


Supplemental Content

Support Center